Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332642 | 0.88 | AR (0.76) | ARMEN1LMNATP53CYP1A2 | |
| SCHEMBL11079218 | 0.83 | AR (1.00) | ARMEN1LMNATP53CYP1A2 | |
| SCHEMBL332918 | 0.82 | AR (0.63) | ARMEN1LMNATP53CYP1A2 | |
| SCHEMBL13581774 | 0.82 | AR (0.63) | ARMEN1LMNATP53CYP1A2 | |
| SCHEMBL332500 | 0.81 | AR (0.73) | ARMEN1LMNATP53CYP1A2 | |
| SCHEMBL11472341 | 0.80 | AR (0.70) | ARMEN1LMNATP53CYP1A2 | |
| SCHEMBL11087769 | 0.76 | AR (0.76) | ARMEN1LMNATP53CYP1A2 | |
| SCHEMBL4031754 | 0.75 | AR (0.79) | ARMEN1LMNATP53CYP1A2 | |
| SCHEMBL6989547 | 0.71 | AR (0.75) | ARMEN1LMNATP53CYP1A2 | |
| SCHEMBL1773488 | 0.71 | AR (0.65) | ARPGRITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097730-B2 | Bicyclic heterocycles useful as selective androgen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| US-8097730-B2 | Bicyclic heterocycles useful as selective androgen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| US-8097730-B2 | Bicyclic heterocycles useful as selective androgen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| EP-1991549-B1 | BICYCLIC IMIDAZOLE OR THIADIAZOLE HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-11 | — | — | EP | disclosed |
| EP-1991549-B1 | BICYCLIC IMIDAZOLE OR THIADIAZOLE HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-11 | — | — | EP | disclosed |
| US-20100160330-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ZHANG XUQING | 2010-06-24 | — | — | US | disclosed |
| US-20100160330-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ZHANG XUQING | 2010-06-24 | — | — | US | disclosed |
| US-20100160330-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ZHANG XUQING | 2010-06-24 | — | — | US | disclosed |
| US-7626036-B2 | 4-(3a-Methyl-1,3-dioxo-5-trifluoromethyl-3a,4-dihydro-3H-1l4-thia-2,6,6a-triaza-pentalen-2-yl)-2-trifluoromethyl-benzonitrile; anticarcinogenic agents; prostate glands; benign prostatic hyperplasia; alopecia; eating disorders; mammary glands; acne; AIDS; cachexia; male contraceptives; sexual disorders | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-01 | — | — | US | disclosed |
| US-7626036-B2 | 4-(3a-Methyl-1,3-dioxo-5-trifluoromethyl-3a,4-dihydro-3H-1l4-thia-2,6,6a-triaza-pentalen-2-yl)-2-trifluoromethyl-benzonitrile; anticarcinogenic agents; prostate glands; benign prostatic hyperplasia; alopecia; eating disorders; mammary glands; acne; AIDS; cachexia; male contraceptives; sexual disorders | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-01 | — | — | US | disclosed |
| US-7626036-B2 | 4-(3a-Methyl-1,3-dioxo-5-trifluoromethyl-3a,4-dihydro-3H-1l4-thia-2,6,6a-triaza-pentalen-2-yl)-2-trifluoromethyl-benzonitrile; anticarcinogenic agents; prostate glands; benign prostatic hyperplasia; alopecia; eating disorders; mammary glands; acne; AIDS; cachexia; male contraceptives; sexual disorders | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-01 | — | — | US | disclosed |
| EP-1991549-A1 | BICYCLIC IMIDAZOLE OR THIADIAZOLE HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007095423-A1 | BICYCLIC IMIDAZOLE OR THIADIAZOLE HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197521-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197521-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197521-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| WO-2007095423-A1 | BICYCLIC IMIDAZOLE OR THIADIAZOLE HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160330-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, FSHR | AR 1/4885MEN1 3463/4885LMNA 3826/4885 |
| US-20070197521-A1 | NOVEL BICYCLIC HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, FSHR | AR 1/4885MEN1 3463/4885LMNA 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.